OR WAIT null SECS
The company is investing in its Capsules and Health Ingredients Division to expand its capsule production capacity by 30 billion capsules annually.
Lonza announced on Oct. 22, 2020 that it is investing $93 million into its Capsules and Health Ingredients Division to expand its capsule production capacity by 30 billion capsules annually.
According to a company press release, the investment will be made over the course of two years at Lonza’s manufacturing sites in Bornem, Belgium; Colmar, France; Greenwood, SC; Haryana, India; Jakarta, Indonesia; Puebla, Mexico; Sagamihara, Japan; and Suzhou, China.
"We continue to see strong demand for our products across all markets, as consumers and patients alike take a more active interest in their health,” said Claude Dartiguelongue, president, Capsules and Health Ingredients, Lonza, in the press release. “Therefore, we felt it is critical that we make this commitment to expand the manufacturing capacity of our network, not only addressing supply needs in the near term but also supply availability over the long term."
"Dosage form technologies have evolved rapidly over the past ten years,” added Stef Vanquickenborne, head of Capsules and Health Ingredients Research and Development, Lonza, in the press release. “As the leader in the industry, we are committed to innovation and helping our customers successfully deliver next-generation drugs and nutritional supplements."